GlassScriptPhysician profile
Soren Caffey
NPI 1760415269
$1,636.23
in general payments reported to CMS, 2019-2025
24 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $22.49 · 2021: $160 · 2022: $280 · 2023: $255 · 2024: $362 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $420.22 | 2019-2025 | Darzalex, Rybrevant |
| Merck Sharp & Dohme LLC | $152.55 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $137.82 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $115.15 | 2022-2024 | |
| Genentech USA, INC. | $106.88 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Abbvie INC. | $94.18 | 2024-2025 | |
| Daiichi Sankyo INC. | $82.48 | 2024-2025 | Enhertu, Datroway |
| Exelixis INC. | $69.87 | 2023-2025 | Cabometyx |
| Gilead Sciences, INC. | $65.07 | 2021-2025 | Trodelvy |
| Incyte Corporation | $47.12 | 2024 | Jakafi |
| Celgene Corporation | $36.52 | 2019 | |
| Mirati Therapeutics, INC. | $36.24 | 2023 | Krazati |
| Menarini Silicon Biosystems, INC. | $33.82 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.18 | 2023 | Alunbrig |
| Coherus Oncology, INC. | $26.39 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $24.03 | 2019 | |
| Spectrum Pharmaceuticals INC. | $23.50 | 2025 | Rolvedon |
| Foundation Medicine, INC. | $23.35 | 2022 | |
| Glaxosmithkline, LLC. | $20.99 | 2025 | Jemperli |
| Octapharma USA, INC. | $20.40 | 2022 | |
| Aveo Pharmaceuticals, INC. | $19.67 | 2021 | |
| Beigene USA, INC. | $17.95 | 2022 | |
| Myriad Genetic Laboratories, INC. | $16.40 | 2022 | |
| Amgen INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soren Caffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.